Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data
Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.
For the final installment of our 3-part relapsed/refractory DLBCL podcast series, CancerNetwork® heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, on treatment strategies for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
These experts spoke about on data regarding tafasitamab (Monjuvi) use in the L-MIND trial (NCT02399085), when to implement CAR-T cell therapies, the role of selinexor (Xpovio), and other important ideas.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens for DLBCL.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
